Header Logo

Parameswaran Venugopal

Concepts (236)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
209
1.920
Why?
Lymphoma, Non-Hodgkin
8
2019
33
1.230
Why?
Leukemia, Myeloid, Acute
5
2021
49
1.210
Why?
Arabinonucleosides
4
2021
6
0.990
Why?
Lymphoma
3
2023
37
0.980
Why?
Lymphoma, Large B-Cell, Diffuse
6
2019
28
0.980
Why?
Antibodies, Monoclonal
8
2011
195
0.980
Why?
Central Nervous System Neoplasms
3
2023
11
0.970
Why?
Rituximab
16
2023
45
0.950
Why?
Antineoplastic Agents
5
2022
175
0.810
Why?
Antibodies, Monoclonal, Murine-Derived
11
2017
29
0.780
Why?
Adenine Nucleotides
2
2010
2
0.700
Why?
Burkitt Lymphoma
3
2021
7
0.570
Why?
Paraproteinemias
2
2019
5
0.550
Why?
Insulin-Like Growth Factor Binding Proteins
1
2015
8
0.500
Why?
Middle Aged
25
2023
8144
0.490
Why?
Insulin-Like Growth Factor I
1
2015
52
0.480
Why?
Adult
21
2021
7089
0.470
Why?
Treatment Outcome
18
2021
3147
0.470
Why?
Humans
43
2023
25227
0.470
Why?
Aged
22
2023
8432
0.440
Why?
Male
25
2022
13573
0.420
Why?
Cyclophosphamide
9
2021
44
0.390
Why?
Necrobiotic Xanthogranuloma
1
2011
1
0.390
Why?
Plasma Cells
1
2011
4
0.390
Why?
Mediastinum
1
2011
6
0.390
Why?
Lymphoma, Mantle-Cell
1
2011
2
0.380
Why?
Female
26
2021
13874
0.370
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2022
14
0.370
Why?
Doxorubicin
7
2021
51
0.350
Why?
Arsenicals
2
2007
10
0.350
Why?
Oxides
2
2007
14
0.350
Why?
Cranial Irradiation
2
2007
10
0.340
Why?
Aged, 80 and over
11
2023
4523
0.340
Why?
Vincristine
7
2019
19
0.330
Why?
Prednisone
7
2019
59
0.320
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
9
0.310
Why?
Cachexia
2
2019
11
0.310
Why?
Disease-Free Survival
7
2021
152
0.300
Why?
Kaplan-Meier Estimate
5
2021
154
0.300
Why?
Leukemia, Myelomonocytic, Acute
1
2007
1
0.290
Why?
Sarcoma, Myeloid
1
2007
4
0.290
Why?
Ear Neoplasms
1
2007
6
0.280
Why?
Lymphoproliferative Disorders
2
2023
13
0.280
Why?
Brain Neoplasms
2
2006
71
0.280
Why?
Recurrence
6
2020
291
0.270
Why?
Epstein-Barr Virus Infections
2
2023
12
0.270
Why?
HIV Infections
2
2021
432
0.270
Why?
Purpura, Thrombotic Thrombocytopenic
1
2006
10
0.260
Why?
Drug Administration Schedule
6
2019
151
0.260
Why?
Combined Modality Therapy
4
2019
268
0.250
Why?
Biomarkers
3
2019
554
0.240
Why?
Immunotherapy
2
2008
51
0.240
Why?
Prognosis
6
2021
727
0.240
Why?
Lymphomatoid Granulomatosis
1
2003
2
0.230
Why?
Lymphoma, B-Cell
3
2008
9
0.220
Why?
Proto-Oncogene Proteins c-myc
2
2021
14
0.210
Why?
Remission Induction
6
2015
86
0.200
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
3
2011
11
0.190
Why?
Drug Resistance, Neoplasm
3
2020
61
0.180
Why?
Thrombosis
1
2021
51
0.180
Why?
Deubiquitinating Enzymes
1
2020
1
0.180
Why?
Benzylidene Compounds
1
2020
1
0.180
Why?
Retrospective Studies
5
2023
3105
0.180
Why?
Azepines
1
2020
3
0.180
Why?
Multiple Myeloma
1
2020
20
0.170
Why?
Young Adult
4
2021
1751
0.170
Why?
Folic Acid Deficiency
1
2019
4
0.170
Why?
Phthalazines
1
2019
4
0.170
Why?
Graft vs Host Disease
1
2020
50
0.170
Why?
Central Nervous System
3
2023
46
0.170
Why?
Respiratory Insufficiency
1
2020
49
0.160
Why?
Proportional Hazards Models
2
2017
315
0.160
Why?
Proto-Oncogene Proteins c-bcl-2
1
2019
18
0.160
Why?
Hematopoietic Stem Cell Transplantation
1
2020
109
0.160
Why?
Piperazines
1
2019
75
0.160
Why?
Neutropenia
4
2012
15
0.160
Why?
Cytosine
2
2021
4
0.150
Why?
Neoplasm Recurrence, Local
3
2021
182
0.150
Why?
Medical Oncology
1
2018
35
0.150
Why?
Kidney Diseases
1
2019
96
0.150
Why?
Cardiology
1
2018
45
0.150
Why?
Immunity
1
2017
16
0.140
Why?
Bendamustine Hydrochloride
1
2016
5
0.140
Why?
Immunocompromised Host
1
2017
43
0.140
Why?
Stroke Volume
1
2016
52
0.140
Why?
Biopsy
2
2019
191
0.130
Why?
Registries
1
2017
161
0.130
Why?
Feasibility Studies
2
2019
195
0.130
Why?
Induction Chemotherapy
1
2015
13
0.120
Why?
Hematologic Neoplasms
1
2014
17
0.120
Why?
Myelodysplastic Syndromes
2
2004
31
0.110
Why?
Metabolic Syndrome
1
2014
53
0.110
Why?
Herpesvirus 4, Human
2
2023
8
0.110
Why?
Leukopenia
2
2011
6
0.110
Why?
Lymphoma, Follicular
2
2011
3
0.110
Why?
Methotrexate
2
2023
36
0.110
Why?
Transcription Factors
2
2004
150
0.110
Why?
Cytarabine
3
2023
11
0.100
Why?
Daunorubicin
2
2015
5
0.100
Why?
Hemoglobinuria, Paroxysmal
1
2012
2
0.100
Why?
Diabetes Mellitus, Type 2
1
2014
167
0.100
Why?
Transcriptome
1
2012
79
0.100
Why?
DNA-Binding Proteins
2
2004
250
0.100
Why?
Obesity
1
2014
266
0.100
Why?
Agranulocytosis
1
2011
3
0.100
Why?
Lymphoma, B-Cell, Marginal Zone
1
2011
6
0.100
Why?
Yttrium Radioisotopes
1
2011
9
0.100
Why?
Fatal Outcome
2
2008
48
0.090
Why?
Cytokines
1
2012
201
0.090
Why?
Retreatment
1
2010
8
0.090
Why?
Salvage Therapy
1
2010
34
0.090
Why?
Pilot Projects
1
2011
361
0.090
Why?
Platelet Count
2
2007
14
0.080
Why?
Infusions, Intravenous
2
2020
46
0.070
Why?
Tomography, X-Ray Computed
1
2011
685
0.070
Why?
Tretinoin
1
2007
14
0.070
Why?
Weight Loss
2
2019
111
0.070
Why?
Injections, Spinal
1
2007
27
0.070
Why?
Follow-Up Studies
1
2011
1622
0.070
Why?
Vascular Neoplasms
1
2006
3
0.070
Why?
Severity of Illness Index
2
2021
903
0.070
Why?
ADAMTS13 Protein
1
2006
5
0.070
Why?
Plasma Exchange
1
2006
10
0.070
Why?
ADAM Proteins
1
2006
46
0.060
Why?
Autoantibodies
1
2006
57
0.060
Why?
Immunosuppressive Agents
2
2023
119
0.060
Why?
Hemoglobins
1
2006
75
0.060
Why?
Survival Analysis
2
2019
233
0.060
Why?
United States
2
2021
1905
0.060
Why?
Radiography
1
2007
572
0.060
Why?
Twins, Dizygotic
1
2005
4
0.060
Why?
Cohort Studies
2
2021
1758
0.060
Why?
Kidney Transplantation
1
2006
112
0.060
Why?
Proto-Oncogenes
1
2004
4
0.060
Why?
Thalidomide
1
2004
5
0.060
Why?
Etoposide
2
2019
24
0.060
Why?
Peripheral Blood Stem Cell Transplantation
1
2004
1
0.060
Why?
Antigens, CD20
1
2003
4
0.060
Why?
Epilepsy, Tonic-Clonic
1
2003
5
0.060
Why?
Vision Disorders
1
2003
18
0.060
Why?
Antigens, Neoplasm
1
2003
36
0.060
Why?
Cyclin D1
1
2003
5
0.060
Why?
Cell Cycle Proteins
1
2003
13
0.060
Why?
K562 Cells
1
2003
3
0.060
Why?
Telomerase
1
2003
9
0.050
Why?
Histones
1
2003
24
0.050
Why?
Apoptosis
1
2003
187
0.050
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2022
1
0.050
Why?
Voriconazole
1
2022
11
0.050
Why?
Cerebral Cortex
1
2003
161
0.050
Why?
Sulfonamides
1
2022
39
0.050
Why?
Risk Factors
2
2005
2175
0.050
Why?
Azacitidine
1
2021
6
0.050
Why?
United Kingdom
1
2021
46
0.050
Why?
L-Lactate Dehydrogenase
1
2021
5
0.050
Why?
Gene Rearrangement
1
2021
9
0.050
Why?
Incidence
1
2023
669
0.050
Why?
Postoperative Complications
1
2006
816
0.040
Why?
Thrombocytopenia
2
2012
20
0.040
Why?
Activities of Daily Living
1
2023
498
0.040
Why?
Folic Acid
1
2019
11
0.040
Why?
Monoclonal Gammopathy of Undetermined Significance
1
2019
2
0.040
Why?
Kidney Function Tests
1
2019
21
0.040
Why?
Maintenance Chemotherapy
1
2019
1
0.040
Why?
Translocation, Genetic
1
2019
5
0.040
Why?
Immunoglobulin A
1
2019
13
0.040
Why?
Maximum Tolerated Dose
1
2019
13
0.040
Why?
Symptom Assessment
1
2019
19
0.040
Why?
Transplantation, Homologous
1
2020
249
0.040
Why?
Anemia
2
2012
88
0.040
Why?
Ovarian Neoplasms
1
2019
42
0.040
Why?
Vidarabine
2
2011
9
0.040
Why?
Lung Neoplasms
1
2003
484
0.040
Why?
Body Composition
1
2019
59
0.040
Why?
Sarcopenia
1
2019
32
0.040
Why?
Interdisciplinary Communication
1
2018
23
0.040
Why?
Magnetic Resonance Imaging
1
2003
1113
0.040
Why?
Mitoxantrone
2
2011
4
0.040
Why?
Cardiologists
1
2018
9
0.040
Why?
Disease Management
1
2019
108
0.040
Why?
Bortezomib
1
2017
3
0.040
Why?
Sex Factors
1
2019
430
0.040
Why?
Prospective Studies
2
2015
1595
0.030
Why?
Tomography, Emission-Computed
2
2006
7
0.030
Why?
Disease Progression
2
2012
650
0.030
Why?
Neoplasms
1
2019
213
0.030
Why?
Recombinant Proteins
2
2008
186
0.030
Why?
Adolescent
1
2021
1998
0.030
Why?
Adenine
1
2015
1
0.030
Why?
Naphthalimides
1
2015
1
0.030
Why?
Organophosphonates
1
2015
1
0.030
Why?
Sensitivity and Specificity
2
2006
467
0.030
Why?
Lipid Metabolism
1
2014
25
0.030
Why?
Insulin Resistance
1
2014
45
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2004
106
0.030
Why?
Cytogenetic Analysis
1
2012
5
0.030
Why?
RNA, Messenger
2
2003
240
0.030
Why?
Signal Transduction
1
2014
380
0.030
Why?
Administration, Oral
1
2012
101
0.030
Why?
Pneumonia
1
2012
66
0.020
Why?
Radiopharmaceuticals
1
2011
46
0.020
Why?
Time Factors
1
2015
1329
0.020
Why?
Nausea
1
2007
23
0.020
Why?
Methylprednisolone
1
2007
20
0.020
Why?
Creatinine
1
2007
43
0.020
Why?
Cisplatin
1
2007
46
0.020
Why?
Animals
1
2014
3382
0.020
Why?
Dose-Response Relationship, Drug
1
2006
307
0.020
Why?
MDS1 and EVI1 Complex Locus Protein
1
2004
3
0.010
Why?
Zinc Fingers
1
2004
12
0.010
Why?
Cell Lineage
1
2004
24
0.010
Why?
Spleen
1
2004
29
0.010
Why?
Teniposide
1
2004
1
0.010
Why?
Bleomycin
1
2004
2
0.010
Why?
Neoplasm Staging
1
2005
294
0.010
Why?
Drug Therapy, Combination
1
2004
162
0.010
Why?
Interferon-alpha
1
2004
30
0.010
Why?
Patient Selection
1
2005
188
0.010
Why?
Transplantation, Autologous
1
2004
144
0.010
Why?
S Phase
1
2003
8
0.010
Why?
E2F Transcription Factors
1
2003
5
0.010
Why?
E2F1 Transcription Factor
1
2003
5
0.010
Why?
Retinoblastoma Protein
1
2003
10
0.010
Why?
Karyotyping
1
2003
8
0.010
Why?
Granulocytes
1
2003
13
0.010
Why?
In Situ Hybridization, Fluorescence
1
2003
29
0.010
Why?
DNA Primers
1
2003
45
0.010
Why?
Bone Marrow Cells
1
2003
47
0.010
Why?
Cell Nucleus
1
2003
74
0.010
Why?
Blotting, Western
1
2003
128
0.010
Why?
Transcription, Genetic
1
2003
86
0.010
Why?
Polymerase Chain Reaction
1
2003
111
0.010
Why?
Bone Marrow
1
2003
73
0.010
Why?
Immunohistochemistry
1
2003
300
0.010
Why?
Acute Disease
1
2003
185
0.010
Why?
Venugopal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (236)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_